Treatment Recommendations for Vaginal Dryness in a Postmenopausal Woman
For a healthy 60-year-old postmenopausal woman with vaginal dryness, offer local low-dose vaginal estrogen as the first-line hormonal treatment—available as cream, tablet, or ring—which has the strongest evidence for effectiveness and safety. 1
Primary Treatment Options
First-Line Hormonal Therapy: Local Low-Dose Vaginal Estrogen
The 2025 AUA/SUFU/AUGS guideline provides a Strong Recommendation for local low-dose vaginal estrogen to treat vaginal dryness, with evidence showing:
- Significant improvement in vaginal dryness without increasing serum estradiol levels
- No increased risk of endometrial hyperplasia or cancer (based on systematic review of 20 RCTs, 10 interventional trials, and 8 observational studies)
- Available in three formulations: cream, tablet, or ring 1
Choose the formulation based on:
- Patient dexterity and ability to apply consistently
- Anatomical considerations
- Patient preference for frequency of application (creams/tablets require more frequent dosing than rings)
Alternative Hormonal Options
If vaginal estrogen is not preferred or contraindicated:
Vaginal DHEA (dehydroepiandrosterone) - Moderate Recommendation
- Statistically significant improvements in vaginal dryness and dyspareunia
- Also improves sexual function, decreases vaginal pH, and improves vaginal epithelial anatomy 1
Ospemifene (oral SERM) - Conditional Recommendation
- May improve vaginal dryness and dyspareunia
- Important caveat: FDA boxed warning for endometrial thickening, increased stroke risk, and deep vein thrombosis risk
- Reserve for patients who cannot or will not use vaginal therapies 1
Non-Hormonal Options
For Symptomatic Relief
Vaginal moisturizers and lubricants should be recommended as adjunctive therapy or primary treatment if hormones are contraindicated 2, 3:
- Moisturizers: Use regularly (2-3 times weekly) for ongoing symptom control
- Lubricants: Use specifically for sexual activity
- Critical selection criteria: Choose products with physiological pH (3.8-4.5) and osmolality to avoid tissue damage 4
- Recent evidence shows long-acting non-hormonal pessaries can provide relief for 11+ hours with twice-weekly application after initial daily use 5
Pelvic Floor Physical Therapy
Consider referral for pelvic floor physical therapy if:
- Concurrent pelvic floor dysfunction or hypertonicity
- Dyspareunia persists despite adequate vaginal lubrication
- Comorbid urinary symptoms (urgency, incontinence) 1, 2
Treatment Algorithm
Step 1: Start with local low-dose vaginal estrogen (cream, tablet, or ring) unless contraindicated
Step 2: Add vaginal moisturizers for additional symptom control between estrogen applications
Step 3: If inadequate response after 8-12 weeks, consider:
- Switching estrogen formulation
- Adding or switching to vaginal DHEA
- Evaluating for concurrent pelvic floor dysfunction
Step 4: Reserve ospemifene for patients who refuse or cannot use vaginal therapies, after discussing thromboembolic and endometrial risks
Important Clinical Considerations
Common pitfall to avoid: The guideline explicitly states there is insufficient evidence to recommend one hormonal therapy over another in terms of comparative efficacy 1. However, local low-dose vaginal estrogen has the greatest amount of evidence and clinical experience, making it the logical first choice.
If patient is already on systemic estrogen therapy for vasomotor symptoms: She may still need local vaginal estrogen or DHEA, as systemic therapy alone often provides inadequate relief of vaginal symptoms 1
Safety reassurance for patient counseling: Multiple studies confirm that local low-dose vaginal estrogen does not increase serum estradiol levels and carries no increased risk of endometrial cancer or hyperplasia when used without progestogen 1